微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 33.66% | 7.59% | -2.51% | 112/160 | 22.89% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 34.53% | 3.58% | -5.83% | 112/160 | 33.26% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 36.67% | 2.17% | 10.11% | 103/160 | 51.37% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 33.3% | 2.69% | 6.44% | 112/160 | 51.37% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 31.29% | 6.73% | -6.14% | 118/160 | 32.75% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 33.33% | 18.45% | -7.12% | 115/160 | 38.61% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 35.89% | 16.96% | 10.67% | 110/160 | 52.91% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 32.43% | 7.36% | 10.63% | 118/160 | 53.57% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 29.31% | -2.81% | 4.16% | 118/160 | 6.69% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 28.14% | -4.36% | -8.29% | 125/160 | 21.79% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 30.69% | 7.34% | 1.59% | 111/160 | 54.47% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 30.21% | -13.56% | 0.15% | 128/160 | 55.07% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 30.16% | -13.04% | 2.51% | 116/160 | 47.01% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 29.42% | -12.69% | 2.93% | 126/160 | 47.45% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 28.59% | -21.22% | -18.19% | 110/160 | 54.21% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 34.94% | 17.49% | 0.75% | 118/160 | -143.08% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 34.68% | 13.62% | 2.92% | 102/160 | 56.57% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 33.7% | 20.22% | -7.13% | 111/160 | 54.32% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 36.29% | 57.17% | 22% | 89/160 | 55.5% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 29.74% | 1.62% | -2.57% | 120/160 | -1204.25% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 30.53% | 8.38% | 8.9% | 96/160 | 55.47% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 28.03% | 3.21% | 21.42% | 107/160 | 55.36% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 23.09% | -9.41% | -21.12% | 98/160 | 51.37% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 29.27% | -20.02% | 3.92% | 119/160 | -205.91% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 28.17% | -25.7% | 3.71% | 92/160 | 54.25% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 27.16% | -30.56% | 6.57% | 100/160 | 53.68% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 25.49% | -34.64% | -30.36% | 95/160 | 54.19% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 36.6% | -5.47% | -3.46% | 87/160 | 52.58% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 37.91% | 2% | -3.08% | 66/160 | 49.32% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 39.11% | -5.14% | 0.31% | 66/160 | 48.02% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 38.99% | 2% | 0.71% | 52/160 | 46.89% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 38.71% | -2.63% | -6.1% | 72/160 | 48.44% | 贝达药业 | 95.58% | 行业排名> |
| 2016-06-30 | 41.23% | -0.32% | 3.7% | 50/160 | 46.2% | 贝达药业 | 95.89% | 行业排名> |
| 2015-12-31 | 39.76% | 2% | -3.88% | 59/160 | 46.24% | 微芯生物 | 97.46% | 行业排名> |
| 2015-06-30 | 41.36% | 2% | 2% | 44/160 | 45.36% | 贝达药业 | 97.01% | 行业排名> |